Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels
Language English Country United States Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't
PubMed
16740970
DOI
10.1210/en.2005-1624
PII: en.2005-1624
Knihovny.cz E-resources
- MeSH
- Adiponectin blood genetics MeSH
- Diet MeSH
- Dietary Carbohydrates administration & dosage MeSH
- Gene Expression drug effects MeSH
- Fenofibrate administration & dosage MeSH
- Glucose Clamp Technique MeSH
- Weight Loss drug effects MeSH
- Insulin blood pharmacology MeSH
- Insulin Resistance * MeSH
- Liver chemistry drug effects MeSH
- Muscle, Skeletal chemistry MeSH
- Blood Glucose analysis MeSH
- Fatty Acids, Nonesterified analysis MeSH
- Lipids biosynthesis MeSH
- RNA, Messenger analysis MeSH
- Mice, Inbred C57BL MeSH
- Mice MeSH
- Obesity blood etiology physiopathology MeSH
- PPAR alpha agonists physiology MeSH
- Receptors, Adiponectin MeSH
- Receptors, Cell Surface genetics MeSH
- Resistin blood genetics MeSH
- Triglycerides blood MeSH
- Adipose Tissue chemistry pathology MeSH
- Organ Size drug effects MeSH
- Fatty Liver blood drug therapy etiology MeSH
- Animals MeSH
- Check Tag
- Male MeSH
- Mice MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Names of Substances
- adiponectin receptor 1, mouse MeSH Browser
- adiponectin receptor 2, mouse MeSH Browser
- Adiponectin MeSH
- Dietary Carbohydrates MeSH
- Fenofibrate MeSH
- Insulin MeSH
- Blood Glucose MeSH
- Fatty Acids, Nonesterified MeSH
- Lipids MeSH
- RNA, Messenger MeSH
- PPAR alpha MeSH
- Receptors, Adiponectin MeSH
- Receptors, Cell Surface MeSH
- Resistin MeSH
- Triglycerides MeSH
We studied the effect of peroxisome proliferator-activated receptor-alpha (PPAR-alpha) activation on serum concentrations and tissue expression of resistin, adiponectin, and adiponectin receptor-1 and -2 (AdipoR1 and AdipoR2) mRNA in normal mice and mice with insulin resistance induced by lipogenic, simple-carbohydrate diet (LD). Sixteen weeks of LD feeding induced obesity with liver steatosis and increased insulin levels but did not significantly affect circulating adiponectin or resistin. Treatment with PPAR-alpha agonist fenofibrate decreased body weight and fat pad weight and ameliorated liver steatosis in LD-fed mice with concomitant reduction in blood glucose, free fatty acid, triglyceride, serum insulin levels, and homeostasis model assessment index values. Euglycemic-hyperinsulinemic clamp demonstrated the development of whole-body and liver insulin resistance in LD-fed mice, which were both normalized by fenofibrate. Fenofibrate treatment markedly increased circulating resistin levels on both diets and adiponectin levels in chow-fed mice only. Fat adiponectin mRNA expression was not affected by fenofibrate treatment. Resistin mRNA expression increased in subcutaneous but not gonadal fat after fenofibrate treatment. In addition to fat, a significant amount of adiponectin mRNA was also expressed in the muscle. This expression markedly increased after fenofibrate treatment in chow- but not in LD-fed mice. Adipose tissue expression of AdipoR1 mRNA was significantly reduced in LD-fed mice and increased after fenofibrate treatment. In conclusion, PPAR-alpha activation ameliorated the development of insulin resistance in LD-fed mice despite a major increase in serum resistin levels. This effect could be partially explained by increased AdipoR1 expression in adipose tissue after fenofibrate treatment.
References provided by Crossref.org